FibroGen Inc (NASDAQ:FGEN) had its Buy rating reiterated by Mizuho with a $74.00 price target

ME Staff
-
0

Analyst Ratings For FibroGen Inc (NASDAQ:FGEN)

Today, Mizuho reiterated its Buy rating on FibroGen Inc (NASDAQ:FGEN) with a price target of $74.00.

There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on FibroGen Inc (NASDAQ:FGEN) is Buy with a consensus target price of $76.3333 per share, a potential 93.00% upside.

Some recent analyst ratings include

  • 12/17/2018-FibroGen Inc (NASDAQ:FGEN) had its Buy rating reiterated by Mizuho with a $74.00 price target
  • 8/8/2018-FibroGen Inc (NASDAQ:FGEN) gets downgraded to Hold by Citigroup with a price target of $71.00
  • 9/14/2017-FibroGen Inc (NASDAQ:FGEN) had its Buy rating reiterated by Stifel Nicolaus with a $80.00 price target
  • 9/12/2017-FibroGen Inc (NASDAQ:FGEN) had its Buy rating reiterated by Jefferies Financial Group with a $75.00 price target
  • 8/9/2017-FibroGen Inc (NASDAQ:FGEN) had its Outperform rating reiterated by William Blair
  • 7/21/2017-FibroGen Inc (NASDAQ:FGEN) gets downgraded to Neutral by Goldman Sachs Group with a price target of $31.00
  • On 12/6/2018 Thomas B Neff, CEO, sold 30,000 with an average share price of $40.93 per share and the total transaction amounting to $1,227,900.00.
  • On 11/21/2018 Thomas B Neff, CEO, sold 39,636 with an average share price of $39.37 per share and the total transaction amounting to $1,560,469.32.
  • On 11/15/2018 Kalevi Kurkijarvi, Director, sold 4,000 with an average share price of $39.77 per share and the total transaction amounting to $159,080.00.
  • On 11/2/2018 Thomas B Neff, CEO, sold 39,636 with an average share price of $44.32 per share and the total transaction amounting to $1,756,667.52.
  • On 10/18/2018 Kalevi Kurkijarvi, Director, sold 4,000 with an average share price of $55.42 per share and the total transaction amounting to $221,680.00.
  • On 10/18/2018 Thomas B Neff, CEO, sold 18,900 with an average share price of $54.52 per share and the total transaction amounting to $1,030,428.00.
  • On 10/3/2018 Thomas B Neff, CEO, sold 39,636 with an average share price of $59.15 per share and the total transaction amounting to $2,344,469.40.

About FibroGen Inc (NASDAQ:FGEN)
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Recent Trading Activity for FibroGen Inc (NASDAQ:FGEN)
Shares of FibroGen Inc closed the previous trading session at 39.55 up +0.18 0.46% with 551200 shares trading hands.